Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies

Author:

Sarrazin Christoph,Isakov Vasily,Svarovskaia Evguenia S.,Hedskog Charlotte,Martin Ross,Chodavarapu Krishna,Brainard Diana M.,Miller Michael D.,Mo Hongmei,Molina Jean-Michel,Sulkowski Mark S.

Funder

Gilead Sciences

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference35 articles.

1. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

2. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

3. Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

4. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study

5. Abergel A , Loustaud-Ratti V , Metivier S et al . Ledipasvir/sofosbuvir for the treatment of patients with chronic genotype 4 or 5 HCV infection. In: International Liver Congress 2015, 50th Annual Meeting of the European Association for the Study of the Liver; 22–26 April 2015; Vienna, Austria.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3